Cancer vaccines train the immune system to combat foreign invaders like tumours, enhancing the body's ability to recognize ...

If prostate cancer spreads to other parts of the body, it can become deadly and commonly moves to bones, the lungs, lymph ...

Gilead, manufacturer of the TROP2-directed antibody-drug conjugate sacituzumab govitecan, made the decision to withdraw the ...

Aged just 48, the 11-time Olympic gold medallist tragically has an incurable version of the disease which is expected to hit ...

While prostate cancer is typically diagnosed in men aged 70 plus there have dramatic increases in the disease in patients ...

Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences ...

The FDA approved a wearable tumor-treating fields (TTFields) device (Optune Lua) for concurrent use with a PD-1/PD-L1 ...

Ruined credit scores and big risks for bankruptcy: All part of the long-term financial fallout from the words "You have ...

Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory ...

The NDA has been accepted for UGN-102 for intravesical solution for low-grade intermediate-risk non-muscle invasive bladder cancer.

The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for ...